The Editor in Chief

World Journal of Hepatology

Dear Editor,

Enclosed please find our revised manuscript entitled "Liver dysfunction during COVID-19 pandemic: contributing role of the associated factors in disease progression and severity". As suggested by the Editor, we have revised the paper. Our point-by-point replies to the reviewers are as follow:

Comment 1: The language and grammar should be checked thoroughly. Few examples

- COVID-19 should be written in uppercase throughout the manuscript
- However, there are many un answerd question which needs to answer.
- We also evaluates the findings for viral infection of hepatocytes.

Please check the manuscript for such errors.

Answer: Thank you for the detailed review as per the suggestion we have checked the language and grammar and corrected the mistakes.

Comment 2: The introduction section needs to be re-written. The introduction is vague at its present form. Please include some statistics in a bar/ pie chart form of the population infected with severe Lung infection and the number of deaths that occurred due to it.

Ans. We have re-written the introduction portion and includes statistical data.

Comment 3: Mechanisms of liver injury during COVID-19. The authors should include a schematic representation of the mechanism.

Ans. We have incorporated the schematic mechanism in figure 1.

Comment 4: What id the source of Figure 1. Has it been created by the authors or copied from somewhere else?

Answer: "Created with BioRender.com". We have the Licensing rights for publication of this figure in the World Journal of Hepatology.

49 Spadina Ave. Suite 200 Toronto ON M5V 2J1 Canada www.biorender.com



Confirmation of Publication and Licensing Rights

January 31st, 2022 Science Suite Inc.

Subscription:Postdoc PlanAgreement number:CP23/8OH7T


Journal name: World Journal of Hepatology

To whom this may concern,

This document is to confirm that Babita Pande has been granted a license to use the BioRender content, including icons, templates and other original artwork, appearing in the attached completed graphic pursuant to BioRender's <u>Academic License Terms</u>. This license permits BioRender content to be sublicensed for use in journal publications.

All rights and ownership of BioRender content are reserved by BioRender. All completed graphics must be accompanied by the following citation: "Created with BioRender.com".

BioRender content included in the completed graphic is not licensed for any commercial uses beyond publication in a journal. For any commercial use of this figure, users may, if allowed, recreate it in BioRender under an Industry BioRender Plan.



For any questions regarding this document, or other questions about publishing with BioRender refer to our <u>BioRender Publication Guide</u>, or contact BioRender Support at <u>support@biorender.com</u>.

Comment 5: In Future directions, why are the authors specifically commenting on the use of herbal medicines? Have the Chinese medicines made it into the clinical trials? Please include relevant statistics.

Answer. Herbal plants have medicinal properties like antiviral, antimicrobial, antibiotics etc due to bioactive compounds. Reports are there that showed efficacy of herbal plants in the prevention and treatment of the COVID-19 (Chaachouay et al., 2021; Khanna et al., 2020). The combined treatment of herbal and Western medicine also helps in reducing the treatment duration and faster recovery from COVID-19 (Ang et al., 2020). For more clarification we have added the recent findings on treatment of COVID-19 using herbal products.

Through the randomized controlled trials the integrated therapy including treatment with both Western as well as herbal medicine have also shown to faster recovery, reduce symptoms and duration of treatment time from COVID-19 (Ang et al., 2020). However, some traditional Chinese herbal medicines suspected to impose side effects and increase the disease course (Yang, 2020). The MACH-19 (Mushrooms and Chinese Herbs for COVID-19) trials are undergoing that could be used as potential adjuvant to COVID-19 vaccines (Slomski, 2021).

Comment 6: The research in liver health should be broadened. There are numerous studies on liver health, the authors should connect those findings and explain how could it help liver problems caused by COVID-19.

Ans. As per the reviewer's suggestion we have incorporated some of the reports as illustrative examples that could be alleviate the liver problems caused by COVID-19.